Bladder Cancer [clinicaltrials_resource:fa9e95e7de270d7a04335ba941650bef]
Evaluation for NCI Surgery Branch Clinical Studies [clinicaltrials:NCT00001823]Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer [clinicaltrials:NCT00002490]Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer [clinicaltrials:NCT00002520]Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer [clinicaltrials:NCT00002684]Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract [clinicaltrials:NCT00002914]Paclitaxel in Treating Patients With Early-Stage Bladder Cancer [clinicaltrials:NCT00002917]Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer [clinicaltrials:NCT00002919]clinicaltrials:NCT00002949Surgery and BCG in Treating Patients With Bladder Cancer [clinicaltrials:NCT00002990]Chemotherapy in Treating Patients With Solid Tumors [clinicaltrials:NCT00003103]Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer [clinicaltrials:NCT00003105]Chemotherapy in Treating Patients With Early-Stage Bladder Cancer [clinicaltrials:NCT00003129]Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer [clinicaltrials:NCT00003133]Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer [clinicaltrials:NCT00003175]Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer [clinicaltrials:NCT00003342]Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium [clinicaltrials:NCT00003376]Antineoplaston Therapy in Treating Patients With Stage IV Bladder Cancer or Stage IV Newly Diagnosed, Incurable Bladder Cancer [clinicaltrials:NCT00003452]Docetaxel in Treating Patients With Solid Tumors [clinicaltrials:NCT00003565]High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer [clinicaltrials:NCT00003623]Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer [clinicaltrials:NCT00003640]Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer [clinicaltrials:NCT00003642]Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer [clinicaltrials:NCT00003657]Combination Chemotherapy in Treating Patients With Bladder Cancer [clinicaltrials:NCT00003701]Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer [clinicaltrials:NCT00003725]AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer [clinicaltrials:NCT00003759]Biological Therapy in Treating Patients With Bladder Cancer [clinicaltrials:NCT00003779]Eflornithine in Treating Patients With Bladder Cancer [clinicaltrials:NCT00003814]clinicaltrials:NCT00003824clinicaltrials:NCT00003930Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer [clinicaltrials:NCT00004065]Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors [clinicaltrials:NCT00004095]BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer [clinicaltrials:NCT00004122]Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer [clinicaltrials:NCT00004154]clinicaltrials:NCT00004203Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer [clinicaltrials:NCT00004223]4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer [clinicaltrials:NCT00005047]clinicaltrials:NCT00005086Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function [clinicaltrials:NCT00005644]LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer [clinicaltrials:NCT00005858]Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer [clinicaltrials:NCT00005958]
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT01928394 [clinicaltrials_resource:10896edf7f8ce192744653721b03b3fc]eligibility for clinicaltrials:NCT00859768 [clinicaltrials_resource:d0ebd44c7f48063c1d8d4281b890a80e]eligibility for clinicaltrials:NCT01432067 [clinicaltrials_resource:e9d0867f15f5e1e12a8f5aef5fa3157a]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT01928394 [clinicaltrials_resource:10896edf7f8ce192744653721b03b3fc]eligibility for clinicaltrials:NCT00859768 [clinicaltrials_resource:d0ebd44c7f48063c1d8d4281b890a80e]eligibility for clinicaltrials:NCT01432067 [clinicaltrials_resource:e9d0867f15f5e1e12a8f5aef5fa3157a]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Bladder Cancer [clinicaltrials_resource:fa9e95e7de270d7a04335ba941650bef]
Bio2RDF identifier
fa9e95e7de270d7a04335ba941650bef
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fa9e95e7de270d7a04335ba941650bef
identifier
clinicaltrials_resource:fa9e95e7de270d7a04335ba941650bef
title
Bladder Cancer
@en
type
label
Bladder Cancer [clinicaltrials_resource:fa9e95e7de270d7a04335ba941650bef]
@en